American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM-III). Washington, DC: APA.
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-III-R). Washington, DC: APA.
Bayer, R. & Spitzer, R. (1985) Neurosis, psychodynamics and DSM-III: a history of the controversy. Archives of General Psychiatry, 42, 187–196.
Bieleski, R. J. & Friedel, R. O. (1976) Predictions of tricyclic antidepressant response. Archives of General Psychiatry, 33, 1479–1489.
Bloch, R. G., Doonief, A. S., Bucberg, A. S., et al (1954) The clinical effect of isoniazid and iproniazid in the treatment of pulmonary tuberculosis. Annals of Internal Medicine, 40, 881–900.
Crane, G. E. (1957) Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiatric Research Reports, 8, 142–152.
Dally, P. & Rhode, P. (1961) Comparison of antidepressant drugs in depressive illness. Lancet, i, 18–20.
Davidson, J. R., Miller, R. D., Turnbull, C. D., et al (1982) Atypical depression. Archives of General Psychiatry, 39, 527–534.
Deragotis, L. R., Lipman, R. S. & Covi, M. D. (1973) Symptom checklist-90 (SCL-90), an out-patient rating scale: preliminary report. Psychopharmacology Bulletin, 9, 13–20.
Fischer, R. A. (1970) Statistical Methods for Research Workers (14th edn), pp. 99–101. New York: Hafner Press.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology, pp. 217–222. Rockville: US Department of Health, Education and Welfare.
Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6, 278–296.
Joyce, P. R. & Paykel, E. S. (1989) Predictors of drug response in depression. Archives of General Psychiatry, 46, 89–99.
Klein, D. F. (1964) Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia, 5, 397–408.
Klein, D. F., Gittelman, R., Quitkin, F. M., et al (1980) Diagnosis and Drug Treatment of Psychiatric Disorders: Adults and Children (2nd edn). Baltimore: Williams & Wilkins.
Kline, N. S. (1958) Clinical experience with oproniazid (Marsilid). Journal of Clinical Experimental Psychopathology, 19 (suppl. 1), 72–78.
Liebowitz, M. R., Quitkin, F. M., Stewart, J. W., et al (1988) Antidepressant specificity in atypical depression. Archives of General Psychiatry, 45, 129–137.
McGrath, P. J., Stewart, J. W., Harrison, W., et al (1987) Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacology Bulletin, 23, 169–172.
McNair, D. M. & Kahn, R. J. (1981) Imipramine with benzodiazepines for agoraphobia. In Anxiety: New Research and Changing Concepts (eds Klein, D. F. & Rabkin, J. G.). New York: Raven Press.
Paykel, E. S., Rowan, P. R., Parker, R. R., et al (1982) Response to phenelzine and amitriptyline in subtypes of outpatient depression. Archives of General Psychiatry, 39, 1041–1049.
Polit, J. & Young, J. (1971) Anxiety state or masked depression: a study based on the action of monoamine oxidase inhibitors. British Journal of Psychiatry, 119, 143–149.
Quitkin, F. M., Rifkin, A. & Klein, D. F. (1979) Monoamine oxidase inhibitors: a review of antidepressant effectiveness. Archives of General Psychiatry, 36, 749–760.
Quitkin, F. M., Stewart, J. S., McGrath, P. J., et al (1988) Phenelzine versus imipramine in the treatment of probable atypical depression; defining syndrome boundaries of selective MAOI responders. American Journal of Psychiatry, 145, 306–311.
Quitkin, F. M., McGrath, P. J., Stewart, J. W., et al (1989) Phenelzine and imipramine in mood reactive depressives: further delineation of the syndrome of atypical depression. Archives of General Psychiatry, 46, 787–793.
Quitkin, F. M., McGrath, P. J., Stewart, J. W., et al (1990) Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Archives of General Psychiatry, 47, 935–941.
Quitkin, F. M., Harrison, W., Stewart, J. W., et al (1991) Response to phenelzine and imipramine in placebo non-responders with atypical depression: a new application of the crossover design. Archives of General Psychiatry, 48, 319–323.
Ravaris, C. L., Robinson, D. S., Ivest, J. O., et al (1980) Phenelzine and amitriptyline in the treatment of depression: a comparison of present and past studies. Archives of General Psychiatry, 37, 1075–1080.
Reimherr, R. W., Wood, D. R., Byerley, B., et al (1984) Characteristics of responders to fluoxetine. Psychopharmacology Bulletin, 20, 70–72.
Robins, E. & Guze, S. B. (1970) Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. American Journal of Psychiatry, 126, 107–111.
Rowan, P. R., Paykel, E. S. & Parker, R. R. (1982) Phenelzine and amitriptyline: effects of symptoms of neurotic depression. British Journal of Psychiatry, 140, 475–483.
Sargent, W. (1961) Drugs in the treatment of depression. British Medical Journal, i, 225–227.
Selikoff, I. J., Robitzek, E. H. & Ornstein, G. G. (1952) Toxicity of hydrazine derivatives of isonicotinic acid in the chemotherapy of human tuberculosis. Quarterly Bulletin Sea View Hospital, 13, 17.
Stewart, J. S., McGrath, P. J., Quitkin, F. M., et al (1989) Relevance of DSM-III depressive subtype and chronicity to antidepressant efficacy in atypical depression: differential response to phenelzine, imipramine and placebo. Archives of General Psychiatry, 46, 1080–1087.
West, E. D. & Dally, P. J. (1959) Effects of iproniazid in depressive syndrome. British Medical Journal, i, 1491–1494.
Young, J. P. R., Lader, M. H. & Hughes, W. C. (1979) Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed out-patients. British Medical Journal Clinical Research, 2, 1315–1317.
Zeller, E. A., Barsky, J., Fouts, J. R., et al (1952) Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinyl 2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experientia, 8, 349–350.
Zitrin, C. M., Klein, D. F. & Woerner, M. G. (1978) Behavior therapy, supportive psychotherapy, imipramine and phobia. Archives of General Psychiatry, 35, 307–315.